April 10th 2024
From our April cover feature: Take an in-depth look at the basis of Valisure's benzene testing methods and practical recommendations for clinicians from Christopher Bunick, MD, PhD.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
How has telemedicine impacted patient visits?
August 12th 2020Julie Harper, M.D., owner and president of the Dermatology and Skin Cancer Center of Birmingham in Alabama, discusses how she approaches treating acne via virtual visits after incorporating telemedicine into her practice due to the COVID-19 pandemic.
A ‘biomarker’ of psychiatric adverse effects with isotretinoin?
July 17th 2020While recognizing that a patient’s mental health generally improves with isotretinoin use due to improvement in acne symptoms, clinicians may consider screening for insomnia during the course of treatment, as it may be an indicator for vulnerability to side effects, researchers say.
Researchers encourage reporting on hormone therapy in acne trial demographics
July 16th 2020Many current acne clinical trials do not consider those patients already on hormone therapy, which researchers say may affect therapeutic outcomes. Authors of a recent study encourage this reporting in future studies to help clinicians better assess how the data might represent a practice population.
FDA approves new label for sarecycline
June 29th 2020Almirall announces the U.S. Food and Drug Administration has approved the updated label for their oral antibiotic sarecycline (Seysara) for treatment of acne vulgaris to help promote the appropriate use of the drug to aid in preventing antimicrobial resistance commonly warned when using antibiotics
FDA approves Aleor’s adapalene gel for acne vulgaris
June 26th 2020The U.S. Food and Drug Administration has approved the Abbreviated New Drug Application for topical retinoid adapalene gel USP, 0.3% from Alembic Pharmaceuticals and its joint venture Aleor Dermaceuticals for treatment of acne vulgaris.
Tazarotene topical for acne vulgaris launches in United States
June 25th 2020Tazarotene lotion 0.045% (Arazlo, Ortho Dermatologics) is officially launched in the U.S. following approval by the U.S. Food and Drug Administration in late 2019 for the treatment of acne vulgaris in patients 9 years and older.
Trifarotene cream proves safe, effective for acne vulgaris
May 11th 2020A recent clinical review proves trifarotene 0.005% cream is an effective and safe treatment for acne vulgaris on the face and neck in patients 9 years and older. Currently, the drug is one of four topical retinoid acne treatments available on the market.
Menlo and Cutia enter agreement for topical minocycline products
April 24th 2020Menlo Therapeutics announces its wholly-owned subsidiary Foamix Pharmaceuticals Ltd. is entering a licensing with Cutia Therapeutics for the company’s FDA-approved 4% topical minocycline foam (AMZEEQ, Foamix) for acne vulgaris in pediatric and adult patients.
Novel acne gel offers more tolerable treatment option
February 21st 2020A novel gel formulation combining tretinoin 0.04% and clindamycin 1% using a controlled release microsphere delivery system effectively treats acne vulgaris without the skin irritation associated with topical tretinoin alone, according to recent data.